Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Diabetic nephropathy; principles of diagnosis and treatment of diabetic kidney disease.

Nazar CM.

J Nephropharmacol. 2014 Jan 1;3(1):15-20. eCollection 2014. Review.

2.

Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis.

Huang R, Feng Y, Wang Y, Qin X, Melgiri ND, Sun Y, Li X.

PLoS One. 2017 Jan 3;12(1):e0168582. doi: 10.1371/journal.pone.0168582. eCollection 2017.

3.

Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes.

Ku E, McCulloch CE, Mauer M, Gitelman SE, Grimes BA, Hsu CY.

Diabetes Care. 2016 Dec;39(12):2218-2224.

4.

Improvements in the Management of Diabetic Nephropathy.

Dounousi E, Duni A, Leivaditis K, Vaios V, Eleftheriadis T, Liakopoulos V.

Rev Diabet Stud. 2015 Spring-Summer;12(1-2):119-33. doi: 10.1900/RDS.2015.12.119. Epub 2015 Aug 10. Review.

5.

Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences.

Lozano-Maneiro L, Puente-GarcĂ­a A.

J Clin Med. 2015 Nov 9;4(11):1908-37. doi: 10.3390/jcm4111908. Review.

6.

Management of diabetic renal disease.

Eboh C, Chowdhury TA.

Ann Transl Med. 2015 Jul;3(11):154. doi: 10.3978/j.issn.2305-5839.2015.06.25. Review.

7.

Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial.

Takihata M, Nakamura A, Kondo Y, Kawasaki S, Kimura M, Terauchi Y.

PLoS One. 2015 May 4;10(5):e0125519. doi: 10.1371/journal.pone.0125519. eCollection 2015.

8.

Blood pressure control for diabetic retinopathy.

Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN.

Cochrane Database Syst Rev. 2015 Jan 31;1:CD006127. doi: 10.1002/14651858.CD006127.pub2. Review.

9.

Clinical therapeutic strategies for early stage of diabetic kidney disease.

Kitada M, Kanasaki K, Koya D.

World J Diabetes. 2014 Jun 15;5(3):342-56. doi: 10.4239/wjd.v5.i3.342. Review.

10.

Therapeutic management of diabetic kidney disease.

Koya D, Araki S, Haneda M.

J Diabetes Investig. 2011 Aug 2;2(4):248-54. doi: 10.1111/j.2040-1124.2011.00112.x. Review.

11.

Therapeutic approaches to slowing the progression of diabetic nephropathy - is less best?

Vivian E, Mannebach C.

Drugs Context. 2013 Mar 27;2013:212249. doi: 10.7573/dic.212249. eCollection 2013 Mar 27. Review.

12.

Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes.

Krolewski AS, Gohda T, Niewczas MA.

Clin Exp Nephrol. 2014 Aug;18(4):571-83. doi: 10.1007/s10157-013-0900-y. Epub 2013 Nov 12. Review.

13.

Management of Diabetic Nephropathy in the Elderly: Special Considerations.

Abdel-Rahman EM, Alhamad T, Reeves WB, Awad AS.

J Nephrol Ther. 2012 Oct;2(5). pii: 124.

14.

Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes.

Weil EJ, Fufaa G, Jones LI, Lovato T, Lemley KV, Hanson RL, Knowler WC, Bennett PH, Yee B, Myers BD, Nelson RG.

Diabetes. 2013 Sep;62(9):3224-31. doi: 10.2337/db12-1512. Epub 2013 Apr 1. Erratum in: Diabetes. 2018 Jan 5;:.

15.

Therapeutic Modalities in Diabetic Nephropathy: Future Approaches.

Reeves WB, Rawal BB, Abdel-Rahman EM, Awad AS.

Open J Nephrol. 2012 Jun 25;2(2):5-18.

16.

Glycemic control modifies the association between microalbuminuria and c-reactive protein in Type 2 Diabetes Mellitus.

Bhowmick K, Kutty AV, Shetty HV.

Indian J Clin Biochem. 2007 Sep;22(2):53-9. doi: 10.1007/BF02913314.

17.

Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.

Abdel-Rahman EM, Saadulla L, Reeves WB, Awad AS.

J Gen Intern Med. 2012 Apr;27(4):458-68. doi: 10.1007/s11606-011-1912-5. Epub 2011 Oct 18. Review.

18.

Effects of spironolactone and losartan on diabetic nephropathy in a type 2 diabetic rat model.

Lee MY, Shim MS, Kim BH, Hong SW, Choi R, Lee EY, Nam SM, Kim GW, Shin JY, Shin YG, Chung CH.

Diabetes Metab J. 2011 Apr;35(2):130-7. doi: 10.4093/dmj.2011.35.2.130. Epub 2011 Apr 30.

19.

Endothelial factors and diabetic nephropathy.

Karalliedde J, Gnudi L.

Diabetes Care. 2011 May;34 Suppl 2:S291-6. doi: 10.2337/dc11-s241. No abstract available.

20.

Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes.

Gnudi L, Goldsmith D.

F1000 Med Rep. 2010 Mar 15;2. pii: 18. doi: 10.3410/M2-18.

Supplemental Content

Support Center